Prevalence of IgA Anti-tissue Transglutaminase Antibody in a Cohort of Iranians Patients with Inflammatory Bowel Disease

• Published in: Journal of Coloproctology 2023-12, Vol.43 (4), p.e280-e285
• Main Authors: Memar, Bahram, Naghavi, Maryam, Vosoughinia, Hassan, Amouian, Sakineh, Farzanehfar, MohammadReza, Namdar, Ali Beheshti, Ahadi, Mitra, Mehrad-Majd, Hassan
• Format: Article
• Language: English
• Subjects: Celiac disease; Crohn's disease; GASTROENTEROLOGY & HEPATOLOGY; IgA anti-tissue transglutaminase; inflammatory bowel disease; SURGERY; ulcerative colitis
• ISSN: 2237-9363; 2317-6423; 2317-6423
• DOI: 10.1055/s-0043-1776888

Background and Aims Some studies have reported the coexistence of inflammatory bowel disease (IBD) and celiac disease (CD). However, the prevalence of anti-tissue transglutaminase antibodies (IgA and IgG) and their screening value in patients with IBD is not yet clear. This study aimed to assess the prevalence of IgA anti-tTG and its potential correlation with disease status in patients with IBD. Materials and Methods This cross-sectional study was conducted on 110 patients with confirmed IBD diagnosis at Ghaem Hospital, Mashhad, Iran. For each patient, all demographic and clinical data including age, extra intestinal manifestations, underlying diseases, types of diseases, and surgical history were collected. IgA anti-tissue transglutaminase titers were assessed by enzyme-linked immunosorbent assay. Results None of the patients with IBD were positive for IgA anti-tTG antibodies, with a mean titer of 3.31 ± 1.3 AU/mL. Also, the mean titers were not associated with age, gender and various disease clinical features including the disease history, underlying disease, diagnosis type, extraintestinal manifestations, and surgery history. Conclusion No significant prevalence pattern of IgA anti-tTG antibody was observed in patients with IBD. Accordingly, serological screening for CeD is not recommended in IBD patients, unless in a relevant clinical CeD suspicion.